Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Annual Meeting Voting Results Announced
Summary
Apellis Pharmaceuticals, Inc. reported the results of its Annual Meeting of Stockholders held on June 3, 2025. The meeting included the election of three new Class II directors: A. Sinclair Dunlop, Alec Machiels, and Keli Walbert, each receiving over 75% of the votes cast. Additionally, the stockholders ratified the appointment of Deloitte & Touche LLP as the independent auditors and approved the advisory vote on executive compensation with over 90% approval. They also recommended that future advisory votes on executive compensation be held annually.
Profitelligence Alerts
Get alerts for APLS
Be first to know when Apellis Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medicines leveraging targeted inhibition of the complement system, a key component of the immune system that plays a crucial role in a variety of diseases. The company's flagship product, targeting diseases such as geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), highlights its commitment to addressing unmet medical needs with innovative treatments. Apellis Pharmaceuticals operates in the highly competitive pharmaceutical and biotechnology industry, collaborating with healthcare providers and research institutions to advance clinical treatment options. Headquartered in Waltham, Massachusetts, its contributions to medical science are significant, paving the way for advancements in immunology and therapy development. As a publicly traded entity, Apellis influences the healthcare sector by enhancing treatment paradigms and offering new hope for patients with chronic and debilitating conditions.
Official SEC Documents
Advertisement